Programmable RNA therapeutics designed with generative AI
Therna Biosciences is a San Francisco-based TechBio company pioneering programmable RNA therapeutics by pairing deep RNA biology with generative AI. Its biology-guided, lab-in-the-loop platform designs precisely engineered mRNA molecules — optimized for translation, stability, immune evasion, and tissue-specific expression — and identifies optimal target sites for ASO and siRNA design. Founded in 2023 by serial biotech entrepreneur Nazli Azimi (CEO) alongside UCSF/Arc Institute RNA scientist Hani Goodarzi and Sasan Amini, the company emerged from stealth in August 2025 with a $10M seed round led by AIX Ventures, Pear VC, and Fusion Fund. In March 2026 it partnered with Charles River to advance single-patient RNA medicines for ultra-rare disorders — designing a lung-fibrosis mRNA candidate in three days — and expanded its leadership team alongside a University of Pennsylvania collaboration. The company is building its therapeutic pipeline and lining up a Series A within roughly 18 months of the seed.
Biotech📍 San Francisco, CAFounded 2023
Current Valuation
Private
as of 2025-Q3
PRIVATE
IPO Outlookprivate
Is Therna Biosciences going public?
No. Therna Biosciences is private and has not filed to go public. There is no S-1 on file.
What is Therna Biosciences' valuation in 2026?
No confirmed valuation is on record for Therna Biosciences. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Therna Biosciences filed an S-1?
No public S-1 is on file for Therna Biosciences.
Who are Therna Biosciences' investors?
Therna Biosciences' investors include AIX Ventures, Pear VC, Fusion Fund, Harmonix Fund, Humba Ventures, Refactor Capital and 1 more.
How much has Therna Biosciences raised?
Therna Biosciences has raised $10M in total across 1 disclosed round, most recently a Seed of $10M in Aug 2025.
Is Therna Biosciences publicly traded — can you buy Therna Biosciences stock?
No. Therna Biosciences is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Therna Biosciences on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Nazli Azimi
Founded
2023
HQ
San Francisco, CA
Total Raised
$10M
Growth
Pre-clinical; Series A targeted within ~18 months of Aug 2025 seed
Last Round
Seed — $10M (Aug 2025) · Lead: AIX Ventures
IPO Status
private
Fundraising Status
Seed · $10M · 1y 1mo ago
privateTotal raised $10M1 disclosed rounds
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Seed
$10M
Aug 2025
AIX Ventures
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Therna Biosciences — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
No public careers page or job board could be found for Therna Biosciences as of 2026-09-14. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Founders & Key People
Nazli AzimiHani GoodarziSasan Amini
Investors
AIX Ventures · Pear VC · Fusion Fund · Harmonix Fund · Humba Ventures · Refactor Capital · Marc Benioff
Products
Generative AI RNA design platform (lab-in-the-loop)
Engineered mRNA therapeutics
ASO / siRNA target-site design
Single-patient RNA medicines for ultra-rare disorders (with Charles River)
Competitors
Atomic AI · Inceptive · Moderna · Generate Biomedicines · Xaira Therapeutics · Orna Therapeutics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q3. Refreshed quarterly.